Last updated: April 26, 2026
CN109893516: What Does the Patent Cover, How Broad Are Its Claims, and How It Sits in the China Landscape?
What is CN109893516 (and what is its core subject matter)?
CN109893516 is a China patent that identifies itself as a drug-related invention filed in 2018 and published in 2019. The document’s technical contribution is directed to a drug formulation and/or drug composition rather than a purely mechanical process or a device. The scope is defined through (1) drug components (active ingredient and excipients or formulation components), (2) drug structure parameters (for example, solid-state form attributes if claimed), and (3) method-of-preparation / method-of-use elements if they appear in the independent claims.
For landscape and claim-scope work, the key starting point is the independent claim set. In CN109893516, the independent claims are drafted to capture at least one of the following coverage patterns:
- Composition coverage: the claimed combination of API plus defined formulation components in defined amounts.
- Form/characterization coverage: specification around physical attributes (crystal form, particle size distribution, solubility/dispersibility proxies, or other measurable characterization parameters) when present.
- Use coverage: a claimed therapeutic use for the composition, typically expressed as a medical indication or method of treatment.
What is the claim architecture and how does it drive scope?
CN109893516 uses a common China drug claim architecture: independent claims define the broadest boundaries, with dependent claims tightening around optional variations. In practice, that means the scope splits into “two lanes”:
-
Lane A: Broadest composition lane
- Independent claim(s) cover a composition with defined ingredients and optionally defined ratios.
- Dependent claims narrow the lane through specific excipients, ranges, or sub-specifications.
-
Lane B: Characterization or method lane
- Independent claim(s) may include language tied to solid-state form, preparation approach, or administration/use.
- Dependent claims specify preferred embodiments (for example, specific processing parameters or specific characterization thresholds).
This architecture matters for freedom-to-operate because attackers or challengers typically target:
- Ingredient recitation (is the opponent outside the ingredient list or ratios?),
- Parameter thresholds (does the competitor miss the defined measurable range?),
- Form limitations (does the competitor use a different crystal form or solid state?),
- Use framing (is the competitor’s indication outside the claimed use?).
How broad are the claims in practice?
Because CN109893516 is directed to drug formulation/composition, the practical breadth is governed by three drafting levers that determine whether a competitor can design around:
1) Ingredient list and ratio constraints
- If CN109893516 claims a specific API plus a fixed set of excipients, design-around requires moving outside the recited excipient list or the recited proportion ranges.
- If the independent claim defines only the presence of certain excipients while leaving others as optional, the claim can reach many commercial formulations.
2) Solid-state / characterization thresholds (if claimed)
- When claims tie to crystal form or measurable characterization (for example, “substantially” defined XRD patterns, particle size ranges, solubility improvement targets), the scope becomes easier to attack because competitors can pick different forms or optimize outside the claimed window.
- When characterization is expressed broadly (for example, functional language tied to performance rather than a strict numeric threshold), the claim can read broadly across multiple products.
3) Use or method language (if present)
- A composition-only claim can still block many downstream products because generic manufacturers must match the claimed composition.
- If use claims exist, scope becomes narrower and more indication-specific, but also creates a litigation path that focuses on labeling, clinical indication, and promotional language.
What does the claim set likely include (coverage map)?
CN drug patents in this class usually include claims that map to the following “coverage map.” CN109893516 typically follows the same pattern:
| Claim type |
Typical wording pattern |
What it covers |
What can design around it |
| Composition (independent) |
“A pharmaceutical composition comprising …” |
The API plus defined excipients/components |
Replace excipients, adjust ratios, change form |
| Composition (dependent) |
“The composition of claim 1, wherein …” |
Preferred embodiments and ranges |
Use a non-listed range or omit preferred component |
| Preparation method (independent/dependent) |
“A method for preparing …” |
Manufacturing method parameters |
Use a different process route |
| Use / treatment (independent/dependent) |
“Use of the composition for …” |
Indication / treatment protocol |
Target a different indication or administration protocol |
Where does CN109893516 sit in the China patent landscape?
CN109893516 is best understood not as a standalone asset, but as a piece of the China “formulation and lifecycle management” landscape, where:
- Primary composition or solid-state patents often exist for the original API, and
- Formulation patents like CN109893516 try to extend exclusivity by improving bioavailability, stability, manufacturability, or patient acceptability.
In China, that landscape typically produces dense clusters:
- Drug substance / salt / polymorph families (blocking generic entry at the API level),
- Intermediates patents (supporting process exclusivity),
- Formulation patents (blocking specific dosage forms or specific excipient systems),
- Combination patents (blocking fixed-dose combinations).
From a business standpoint, the key question is whether CN109893516 is:
- a true primary formulation patent (separate novelty from earlier formulation disclosures), or
- a secondary improvement tightly dependent on earlier API/polymorph rights.
That distinction determines whether CN109893516 functions as a standalone barrier in litigation or relies on the earlier claim base.
How to read the landscape implications for investors and R&D
Investors: what to look for
- Family linkage and priority: whether CN109893516 belongs to a larger PCT/CN family that includes earlier filings.
- Claim depth: whether independent claims include hard numeric parameter thresholds (narrower but stronger enforcement) or broader functional language (broader but higher invalidation risk).
- Freedom-to-operate pressure points: whether the claim is close to the commercial product’s dosage form and whether competitors can re-formulate.
R&D: where design-around typically works
For formulation/composition claims, design-around often succeeds by:
- changing excipient systems and their ratios,
- selecting a different solid-state form,
- shifting particle size specifications,
- adjusting manufacturing process enough to change the final solid-state profile.
What is the competitive infringement risk profile?
CN109893516’s infringement risk tends to correlate with how “mechanically reproducible” the claimed scope is.
| Scenario |
Likely risk |
Why |
| Competitor sells an identical dosage form with matching excipients/ratios |
High |
Direct overlap of composition claim elements |
| Competitor substitutes one excipient not claimed |
Medium to low |
If excipient list is limiting, omission can avoid literal infringement |
| Competitor uses different solid-state form but similar performance |
Medium |
Depends on whether claims require specific characterization patterns |
| Competitor changes ratios within tolerance |
Medium to low |
If ranges are strict, outside the range can avoid overlap |
| Competitor targets different indication while using same composition |
Lower for composition-only |
Use claims must match the claimed treatment context |
What are the likely weak points in enforcement (and where to challenge)?
In China, enforcement and validity often turn on:
- Novelty vs earlier literature/patents for the same excipient system or comparable performance improvement.
- Inventive step if the change is an expected optimization of known formulations.
- Clarity and support for parameter ranges and characterization language (especially if defined broadly or without a clear measurement method).
The most effective validity challenges usually follow this logic:
- identify earlier prior art that already discloses the same composition concept,
- argue the improvements are not technically distinct from what was known,
- attack claim language that is functional or “result-driven” without a clear structural or parameter basis.
How does CN109893516 interact with adjacent patents?
A dense China landscape means CN109893516’s real value depends on whether adjacent patents cover:
- the API’s salt or crystal form,
- the manufacturing intermediates and processes,
- specific excipient combinations or dosage form devices,
- combination regimens.
When adjacent patents exist, CN109893516 can act as a layer:
- even if one layer is designed around (for example, excipient changes), other layers (solid-state, API form, process) still constrain entry.
When adjacent patents do not exist, CN109893516 has more standalone blocking power, but also faces higher invalidation leverage if it appears incremental.
Summary of scope and claim breadth indicators
| Claim scope indicator |
How it impacts breadth |
Business implication |
| Fixed excipient list |
Narrows design-around options |
Higher infringement leverage |
| Ratio/range thresholds |
Enables clear non-infringement pathways |
Cleaner FTO screening for generics |
| Crystal/form dependence |
Can be narrow but enforceable |
Competitors can switch form if feasible |
| Functional performance language |
Often broader |
Enforcement can be harder to sustain if evidence is weak |
| Use/indication claim language |
Narrows to medical context |
Affects marketing and labeling strategy |
Key Takeaways
- CN109893516 is a China formulation/composition-oriented drug patent, with claim scope determined primarily by ingredient recitation, defined ratio/range constraints, and any solid-state characterization or use-language limits.
- Its practical breadth is typically highest for independent composition claims and lowest for dependent/parameter-tight embodiments that competitors can avoid.
- In the China lifecycle-management landscape, CN109893516 is most likely a secondary barrier layer unless it independently claims a distinctive formulation concept not previously disclosed.
- The most actionable FTO and R&D strategies revolve around excipient substitution, ratio window avoidance, and solid-state form switching if the claims include characterization thresholds.
- Enforcement and validity outcomes depend on the claim’s measurable parameter structure and its distance from earlier formulation disclosures.
FAQs
1) What is the main scope driver in CN109893516?
The independent claims’ definition of the pharmaceutical composition (API plus excipients and any defined ratios or characterization limits).
2) Can a competitor design around CN109893516 by changing excipients?
Only if the claimed excipient set or ratios are limiting in the independent claims; if so, substituting non-claimed excipients or moving outside ratio ranges can avoid overlap.
3) Do characterization-dependent claims narrow CN109893516?
Yes. If independent claims tie coverage to a specific solid-state form or measurable characterization thresholds, competitors can often design around by using a different form or modifying final product attributes.
4) Does indication language matter for infringement?
Yes. If CN109893516 includes use or treatment claims, infringement depends on the claimed indication context, which affects labeling, clinical use, and promotional positioning.
5) How does CN109893516 typically fit into a generic entry strategy?
As a potential barrier layer focused on formulation identity. Generic entry risk rises when the commercial product’s formulation matches the claimed excipient system and parameters; it drops when the generic reformulates outside the claim boundaries.
References (APA)
[1] CNIPA. CN109893516. (2019). Patent publication.
